The US biotechnology firm LyGenesis announced that the investment was made by the British Virgin Islands-registered holding company Juvenescence Ltd., in the amount of US$3 million.
LyGenesis is working with lymph nodes to regrow functioning organs with patient’s own body, focusing on patients with end-stage liver condition, and the investment will enable the completion of work required for human clinical trials.
LyGenesis was established on the basis of academic research, which was partially funded by the National Institutes of Health and conducted at Pittsburgh’s McGowan Institute for Regenerative Medicine, and revealed that a variety of different cells types and tissues, including the liver, could engraft and grow within lymph nodes. LyGenesis licensed patents for the technology from Pittsburgh.